Filing Details
- Accession Number:
- 0001104659-18-054143
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-08-29 16:24:48
- Reporting Period:
- 2018-08-27
- Accepted Time:
- 2018-08-29 16:24:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1442836 | Mersana Therapeutics Inc. | MRSN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1709775 | B Timothy Lowinger | C/O Mersana Therapeutics, Inc. 840 Memorial Drive Cambridge MA 02139 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-08-27 | 3,500 | $7.43 | 15,991 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-08-27 | 3,500 | $13.15 | 12,491 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to purchase Common Stock | Disposition | 2018-08-27 | 3,500 | $0.00 | 3,500 | $7.43 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,611 | 2021-05-11 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Dr. Lowinger's company approved trading plan under Rule 10b5-1.
- This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.50, inclusive. The reporting person undertakes to provide to Mersana Therapeutics, Inc., any other security holder of Mersana Therapeutics Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The option vested 25% on May 12, 2012 and in equal quarterly installments thereafter.